Entrada Therapeutics Inc.
Organization details
- Legal name
- Entrada Therapeutics Inc.
- Former names
- CycloPorters, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TRDA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001689375
- EIN
- 81-3983399
Board of directors
-
Bernhardt G. Zeiher · DirectorSince 2023
-
Dipal Doshi · Director · CEOSince 2023
-
Gina Chapman · DirectorSince 2023
-
John F. Crowley · DirectorSince 2023
-
Kush Parmar · DirectorSince 2023
-
Maha Radhakrishnan · DirectorSince 2025
- Since 2023
-
Peter S. Kim · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
91.4%
-
92.0%
Board connections
6 of this board's directors also sit on 11 other boards. 10 are in the same sector.
-
Abeona Therapeutics Inc. Same sectorvia Bernhardt G. Zeiher
-
Aktis Oncology Inc. Same sectorvia Mary Thistle
-
Alaunos Therapeutics Inc. Same sectorvia Mary Thistle
-
Alto Neuroscience Inc. Same sectorvia Maha Radhakrishnan
-
Amylyx Pharmaceuticals Inc. Same sectorvia Bernhardt G. Zeiher
- via Dipal Doshi
-
Candel Therapeutics Inc. Same sectorvia Maha Radhakrishnan
-
Cullinan Therapeutics Inc. Same sectorvia Mary Thistle
-
Intellia Therapeutics Inc. Same sectorvia John F. Crowley
-
Q32 Bio Inc. Same sectorvia Mary Thistle
-
Rallybio Corporation Same sectorvia Kush Parmar
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $291,124
- 5 purchases by 2 insiders
- Sold, last 12 months
- $15,103,785
- 44 sales by 12 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 9, 2026 | MPM BIOVENTURES 2018 (B), L.P. 10% owner | Open-market sale | −28,837 | $7.13 | $205,608 |
| Sep 9, 2026 | MPM BioVentures 2018 GP LLC 10% owner | Open-market sale | −28,837 | $7.13 | $205,608 |
| Sep 8, 2026 | MPM BIOVENTURES 2018 (B), L.P. 10% owner | Open-market sale | −192,500 | $7.41 | $1,426,425 |
| Sep 8, 2026 | MPM BioVentures 2018 GP LLC 10% owner | Open-market sale | −192,500 | $7.41 | $1,426,425 |
| Sep 4, 2026 | MPM BIOVENTURES 2018 (B), L.P. 10% owner | Open-market sale | −38,500 | $7.11 | $273,735 |
| Sep 4, 2026 | MPM BioVentures 2018 GP LLC 10% owner | Open-market sale | −38,500 | $7.11 | $273,735 |
| Sep 3, 2026 | MPM BioVentures 2014 GP LLC 10% owner | Open-market sale | −32,263 | $7.17 | $231,326 |
| Sep 3, 2026 | MPM BioVentures 2018 LLC 10% owner | Open-market sale | −32,263 | $7.17 | $231,326 |
| Sep 2, 2026 | Dipal Doshi Director, Officer (CEO) | Shares withheld for tax | −8,724 | $7.14 | $62,289 |
| Sep 2, 2026 | Dowden Nathan J Officer (President & COO) | Shares withheld for tax | −2,528 | $7.14 | $18,050 |
| Sep 2, 2026 | WENTWORTH KORY JAMES Officer (Chief Financial Officer) | Shares withheld for tax | −1,733 | $7.14 | $12,374 |
| Sep 2, 2026 | Sethuraman Natarajan Officer (President, Research & Develop.) | Shares withheld for tax | −2,079 | $7.14 | $14,844 |
| Sep 2, 2026 | MPM BioVentures 2014 GP LLC 10% owner | Open-market sale | −25,131 | $7.19 | $180,692 |
| Sep 2, 2026 | MPM BioVentures 2018 LLC 10% owner | Open-market sale | −25,131 | $7.19 | $180,692 |
| Sep 1, 2026 | MPM BioVentures 2014 GP LLC 10% owner | Open-market sale | −29,088 | $7.06 | $205,361 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Entrada Therapeutics Inc.
Who is the CEO of Entrada Therapeutics Inc.?
Dipal Doshi is Entrada Therapeutics Inc.'s President and CEO.
How many directors are on Entrada Therapeutics Inc.'s board?
Entrada Therapeutics Inc.'s board has 8 directors: Bernhardt G. Zeiher, Dipal Doshi, Gina Chapman, John F. Crowley, Kush Parmar, Maha Radhakrishnan, Mary Thistle and Peter S. Kim.
Are Entrada Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Entrada Therapeutics Inc. insiders bought $291,124 of shares in 5 purchases and sold $15.1 million of shares in 44 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="entrada-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.